We’re witnessing a renaissance in cytokine targeting,” says Dr. Emily Rhodes, immunologist at the Stanford Institute for ...

All were receiving TNF inhibitors and were in remission or had low disease activity, defined as a DAS28 of3.2 or less. To determine the predictive value of serum calprotectin, TNF inhibitor trough ...

Over the last decade, TNF-α antagonists became the most powerful tools for controlling patient suffering from a number of rheumatic diseases. Infliximab, etanercept and adalimumab can induce ...

Results of the updated systematic review informing the 2024 EULAR recommendations showed that many ARDs are safe to use during pregnancy, lactation, and reproduction.

We’re not intending to capture all possible patients, but those we think would make the best trial candidates so that we can ...

The mechanisms governing immune-related adverse events resulting from checkpoint inhibition therapy for cancer remain a ...

Patients with vitiligo experience impacts on quality of life, emerging therapies offer promising prospects for more targeted ...

Bimekizumab demonstrated a favorable safety profile for the long-term treatment of axSpA and PsA, with rates of TEAEs remaining stable over time.

Tumor necrosis factor-α (TNF-α) is a key cytokine involved in the pathogenesis of ulcerative colitis (UC), a chronic inflammatory bowel disease, and has emerged as a promising therapeutic target.

Drug Farm, a private biotechnology company utilizing genetics and artificial intelligence technologies to discover and develop innovative, immune-modulating therapies, today announced positive results ...

Severe alcohol-associated hepatitis (sAH) remains a highly lethal condition with limited therapeutic options. Characterized by rapid liver ...

Manmeet Ahluwalia, MD, MBA, FASCO, chief of medical oncology, chief scientific officer, and deputy director of the Miami ...